Last reviewed · How we verify

NCT03193892

A National Registry on Chinese Patients With Lymphangioleiomyomatosis

Recruiting now Last updated 24 September 2021
What this trial tests

trial in Pulmonary Function in 1,500 participants. Currently enrolling.

Timeline
1 January 2017
Primary endpoint
1 October 2026
1 October 2026

Quick facts

Lead sponsorPeking Union Medical College Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,500
Start date1 January 2017
Primary completion1 October 2026
Estimated completion1 October 2026
Sites1 location across China

Conditions studied

Sponsor

Peking Union Medical College Hospital

Who can join

Eligibility, female only, with Pulmonary Function. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are to accurately evaluate the prevalence of LAM, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Determinants of Progression and Mortality in Lymphangioleiomyomatosis.
    Xu W, Yang C, Cheng C, Wang Y, et al · · 2023 · cited 24× · PMID 36801466 · DOI 10.1016/j.chest.2023.02.026
  2. Long-term safety and influence on growth in patients receiving sirolimus: a pooled analysis.
    Wang YY, Zou LP, Xu KF, Xu WS, et al · · 2024 · cited 5× · PMID 39148107 · DOI 10.1186/s13023-024-03243-5
  3. Increased malignancy risk in patients with lymphangioleiomyomatosis: findings from a Chinese cohort.
    Zhang X, Cheng C, Wang H, Liu J, et al · · 2025 · cited 1× · PMID 40450294 · DOI 10.1186/s13023-025-03834-w
  4. Associations of VEGF-D levels with clinical manifestations in lymphangioleiomyomatosis: a cross-sectional analysis of 631 cases.
    Yang L, Wang H, Cheng C, Zhang M, et al · · 2025 · cited 1× · PMID 40420164 · DOI 10.1186/s13023-025-03802-4
  5. Six-minute walk distance predicting the risk of mortality in lymphangioleiomyomatosis patients.
    Yang L, Zhang X, Wang L, Cheng C, et al · · 2026 · PMID 41514454 · DOI 10.1186/s13023-026-04194-9

Verify or expand the search:

Other recruiting trials for Pulmonary Function

Currently open trials in the same condition.

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03193892.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing